| Literature DB >> 28924391 |
Yaxiang Shi1, Xuan Chen1, Biao Xi1, Xiaowen Yu1, Jun Ouyang2, Chunxia Han1, Yucheng Qin1, Defeng Wu1, Hong Shen3.
Abstract
BACKGROUND/AIMS: ErbB3 is an oncogene which has proliferation and metastasis promotion effects by several signaling pathways. However, the individual expression difference regulated by miRNA was almost still unknown. We focused on the miRNAs associated SNPs in the 3'-UTR of ErbB3 to investigate the further relationship of the SNPs with miRNAs among Chinese gastric cancer (GC) patients.Entities:
Keywords: 3′-UTR; ErbB3; MiR-204; Survival; miR-211
Year: 2017 PMID: 28924391 PMCID: PMC5599891 DOI: 10.1186/s12935-017-0449-z
Source DB: PubMed Journal: Cancer Cell Int ISSN: 1475-2867 Impact factor: 5.722
List of SNP in 3′UTR region of ErbB3
| SNP | chr | 3′UTR position | Associated miRNA | Allele |
|---|---|---|---|---|
| rs3202538 | 12 | 373–395 | hsa-miR-204 | G/T |
| rs3202538 | 12 | 373–395 | hsa-miR-211 | G/T |
| rs3202538 | 12 | 373–395 | hsa-miR-4287 | G/T |
| rs78743019 | 12 | 1076–1101 | hsa-miR-3170 | A/C |
| rs35291818 | 12 | 102–119 | hsa-miR-4314 | –/C |
Frequency distributions of selected variables in patients and cancer-free controls
| Variables | Cases ( | Controls ( |
| ||
|---|---|---|---|---|---|
|
| % |
| % | ||
| Age (years) | 0.681 | ||||
| ≤50 | 376 | 44.18 | 345 | 43.18 | |
| >50 | 475 | 55.82 | 454 | 56.82 | |
| Gender | 0.286 | ||||
| Male | 318 | 37.37 | 319 | 39.92 | |
| Female | 533 | 62.63 | 480 | 60.08 | |
| Hp infection | <0.0001 | ||||
| Negative | 254 | 29.85 | 550 | 68.84 | |
| Positive | 597 | 70.15 | 249 | 31.16 | |
| Differentiation grade | |||||
| Poor | 214 | 25.15 | |||
| Moderate | 294 | 34.55 | |||
| Well | 343 | 40.31 | |||
| Tumor size (cm) | |||||
| ≤3 | 276 | 32.43 | |||
| >3 | 575 | 67.57 | |||
| Metastasis | |||||
| Yes | 412 | 48.41 | |||
| No | 439 | 51.59 | |||
* Two-sided Chi square test for either genotype distributions or allele frequencies between cases and controls
Genotype frequencies of the ErbB3 at rs3202538 polymorphism among GC cases and controls
| Genotype | Cases ( | Controls ( | OR (95% CI)a |
| ||
|---|---|---|---|---|---|---|
|
| % |
| % | |||
| rs3202538 | ||||||
| GG | 178 | 20.92 | 398 | 49.81 | 1 | <0.0001 |
| GT | 317 | 37.25 | 217 | 27.16 | 1.89 (1.48–2.01) | |
| TT | 356 | 41.83 | 184 | 23.03 | 4.32 (1.34–1.88) | |
| T carrier | 673 | 79.08 | 401 | 50.19 | 3.75 (1.47–2.04) | <0.0001 |
aThe ORs, 95% CIs and P value were calculated after adjusting for age, gender, parental Hp infection history and family cancer history
Stratified analysis of genotypes of ErbB3 rs3202538 with clinicopathological parameters of GC
| Features | Genotype | GG vs GT | GG vs TT | ||
|---|---|---|---|---|---|
| GG | GT | TT | |||
| Age (years) | 0.167 | 0.081 | |||
| ≤50 | 81 | 161 | 134 | ||
| >50 | 97 | 156 | 222 | ||
| Gender | 0.416 | 0.756 | |||
| Male | 75 | 137 | 145 | ||
| Female | 103 | 219 | 211 | ||
|
| 0.002 | 0.169 | |||
| Negative | 48 | 129 | 77 | ||
| Positive | 130 | 188 | 279 | ||
| Differentiation grade | 0.0047 | <0.0001 | |||
| Well | 73 | 94 | 47 | ||
| Moderate | 68 | 117 | 120 | ||
| Poor | 37 | 106 | 189 | ||
| Tumor size (cm) | 0.109 | <0.0001 | |||
| ≤3 | 93 | 164 | 19 | ||
| >3 | 85 | 153 | 337 | ||
| Metastasis | 0.0042 | <0.0001 | |||
| Yes | 49 | 128 | 235 | ||
| No | 129 | 189 | 121 | ||
* Two-sided Chi square test for either genotype distributions or allele frequencies between cases and controls
Fig. 1SNP rs3202538 in ERBB3 3′UTR of GC patients with GT/TT genotype can up-regulate of ERBB3 transcription by deregulated by miR-211 and miR-204. a Bioinformatics predicted the binding site of the miR-204, miR-211 and miR-4287 with ErbB3 and the mutation types were conducted into the pGL3 plasmid as presented. b Cells were cotransfected with miR-204, miR-211 and miR-4287 mimics or control, Renilla luciferase vector pRL-SV40 for 48 h. Both firefly and Renilla luciferase activities were measured in the same sample. Firefly luciferase signals were normalized with Renilla luciferase signals. Data were presented as the mean ± SEM. Asterisk indicates a significant difference (P < 0.05)
Fig. 2G>T of rs3202538 promote cell proliferation and invasion by enhanced ErbB3 expression in miR-211 or miR-204 overexpression GC cell. a, b The cell proliferation was determined for 5 days of the cells treated differently indicated in the figures. c, d The cell metastasis capability of variously treated MKN45 cells were determined by using a trans-well based cell invasion assay. e The expression of ErbB3 as well as activation of AKT signaling pathway in cells treated differently were determined by using western-blot. Data were presented as the mean ± SEM. *P < 0.05 and **P < 0.01
Fig. 3SNP rs3202538 in ERBB3 3′UTR on the expression of ERBB3 in clinical samples. a Representative figures for IHC staining of ERBB3 in GC tumor section. b Comparison of a component of IHC staining in both in TT, GT and GG genotype GC patents. c, d, e The expression level of ERBB3, miR-211 and miR-204 were determined by real-time PCR in different genotypes GC patents
Fig. 4SNP rs3202538 in ERBB3 3′UTR on overall survival and relapse free survival. a, b Overall survival rate and relapse free survival of post-surgery GC patients were analyzed by Kaplan–Meier survival curve. Data were presented as the mean ± SEM. *P < 0.05 and **P < 0.01